Literature DB >> 3385638

Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine.

P W Kalivas1, B Weber.   

Abstract

The daily administration of indirect dopamine agonists, including amphetamine and cocaine, results in a progressive increase in the behavioral stimulant effect of these drugs. Behavioral augmentation also has been shown with opioids such as morphine, and it is known that a stimulant action on dopaminergic perikarya in the ventromedial mesencephalon is critical to the development of behavioral sensitization to morphine. To determine if amphetamine-induced behavioral sensitization might also involve the mesencephalic dopamine neurons, amphetamine was microinjected daily for 2 days into regions of the rat brain containing dopamine cell bodies (A10 and A9 dopamine regions), or dopamine terminals (nucleus accumbens and striatum), and 6 days later amphetamine was given peripherally. It was found that daily amphetamine injection into the A10 or A9 dopamine region, but not into the dopamine terminal fields, significantly potentiated the motor stimulant effect of peripherally administered amphetamine. The behavioral sensitization produced by intracranial injection of amphetamine was found to be dose-dependent. Intra-A10 injection of amphetamine also was found to potentiate the motor stimulant effect of peripheral cocaine. These data indicate that an action by amphetamine in the A10 and A9 dopamine regions may play a critical role in the development of behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385638

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  65 in total

1.  The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system.

Authors:  Heather N Lavezzi; Daniel S Zahm
Journal:  Basal Ganglia       Date:  2011-11

2.  Sex differences in nicotine levels following repeated intravenous injection in rats are attenuated by gonadectomy.

Authors:  Steven B Harrod; Rosemarie M Booze; Charles F Mactutus
Journal:  Pharmacol Biochem Behav       Date:  2006-12-20       Impact factor: 3.533

3.  Appetitive sensitization by amphetamine does not reduce its ability to produce conditioned taste aversion to saccharin.

Authors:  John Scott-Railton; Gretchen Arnold; Paul Vezina
Journal:  Behav Brain Res       Date:  2006-10-04       Impact factor: 3.332

4.  Effects of selective D1 and D2 dopamine antagonists on the development of behavioral sensitization to apomorphine.

Authors:  B A Mattingly; J K Rowlett; J T Graff; B J Hatton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Nucleus accumbens lesions modulate the effects of methylphenidate.

Authors:  Adam Podet; Min J Lee; Alan C Swann; Nachum Dafny
Journal:  Brain Res Bull       Date:  2010-05-12       Impact factor: 4.077

6.  Regulation of netrin-1 receptors by amphetamine in the adult brain.

Authors:  L Yetnikoff; C Labelle-Dumais; C Flores
Journal:  Neuroscience       Date:  2007-10-10       Impact factor: 3.590

7.  Activation of afferents to the ventral tegmental area in response to acute amphetamine: a double-labelling study.

Authors:  Joyce Colussi-Mas; Stefanie Geisler; Luc Zimmer; Daniel S Zahm; Anne Bérod
Journal:  Eur J Neurosci       Date:  2007-08       Impact factor: 3.386

8.  Cross-sensitization of the reinforcing effects of cocaine and amphetamine in rats.

Authors:  Yu Liu; Drake Morgan; David C S Roberts
Journal:  Psychopharmacology (Berl)       Date:  2007-08-22       Impact factor: 4.530

9.  Studies on the role of dopamine D1 receptors in the development and expression of MDMA-induced behavioral sensitization in rats.

Authors:  María Ramos; Beatriz Goñi-Allo; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

10.  Behavioral sensitization to amphetamine is not accompanied by changes in glutamate receptor surface expression in the rat nucleus accumbens.

Authors:  Christopher L Nelson; Michael Milovanovic; Joseph B Wetter; Kerstin A Ford; Marina E Wolf
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.